Novo Nordisk launched the 'Power of Wegovy' national campaign on 2024-06-03, featuring diverse and empowering portrayals of individuals managing obesity. The campaign emphasizes inclusivity and anti-stigma messaging while educating the public on the clinical benefits of Wegovy, reinforcing the value of diverse representation in healthcare.

Novo Nordisk launched the Believe On campaign for Wegovy to reshape the obesity narrative. The campaign emphasizes transparency about supply challenges, supports healthcare professionals, and combats misinformation regarding obesity as a disease, aiming to reduce stigma and better serve affected communities.

Novo Nordisk, the maker of Wegovy, is actively lobbying Congress to change the federal ban that prevents Medicare from covering weight loss drugs. The company is leveraging relationships with the Congressional Black Caucus and associated groups, in addition to providing campaign contributions, to help shift policy in its favor.

Novo Nordisk, the maker behind Wegovy, has engaged in a strategic political outreach by sponsoring panel discussions and partnering with influential Black leaders at events such as the Congressional Black Caucus Foundation conference. The company’s efforts aim to shift public policy towards Medicare coverage of weight loss drugs, thereby expanding its market access. This event highlights significant corporate involvement in political contributions and lobbying to influence public health policy.

The Reuters report details repeated breaches of sterile-safety protocols at the Brussels facility filling Wegovy injection pens, including failures in air-filtration systems and quality checks. This has led to regulatory actions and production delays, raising concerns about the oversight of Wegovy’s manufacturing supply chain and its implications for public health.